Founded 2011 | ||
Galecto biotech in copenhagen science city
Galecto Biotech is a Swedish private biotechnology company that has developed a galectin-3 inhibitor that would prevent fibrosis. The company, founded in 2011, is based in Lund.
The galectin-3 inhibitor, TD139, has the potential to treat many diseases due to its involvement in many key biological pathways such as cell differentiation, cell growth, and apoptosis. Galecto Biotech is using this inhibitor to treat idiopathic pulmonary fibrosis (IPF), which is a progressive, irreversible and ultimately fatal lung disease that has poor prognosis and no effective therapies. Transforming growth factor is a major mediator of fibrosis and galectin-3 expression is highly upregulated in patients with idiopathic pulmonary fibrosis. TD139 galectin-3 inhibitor, reduces the transforming growth factor (TGF)-β signalling, ultimately showing a strong anti-fibrotic potential that may provide a novel treatment for idiopathic pulmonary fibrosis.